Sinil Pharmaceutical Co. Ltd Capital Reinvestment Ratio
Sinil Pharmaceutical Co. Ltd capital reinvestment ratio. Sinil Pharmaceutical Co. Ltd (012790) has a Capital Reinvestment Ratio of 0.08x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩2.62 Billion) in capital expenditures (₩213.15 Million). Check 012790 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Sinil Pharmaceutical Co. Ltd (2014–2024)
Capital reinvestment ratio of Sinil Pharmaceutical Co. Ltd from 2014 to 2024. This chart tracks Sinil Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 11 annual periods. Also explore 012790 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Sinil Pharmaceutical Co. Ltd Capital Reinvestment Ratio by Year (2014–2024)
Sinil Pharmaceutical Co. Ltd capital reinvestment ratio by year from 2014 to 2024. For the full cash flow conversion analysis, see Sinil Pharmaceutical Co. Ltd operating cash flow efficiency.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.37x | ₩22.69 Billion | ₩8.47 Billion | ▼ -56.2% |
| 2023 | 0.85x | ₩15.15 Billion | ₩12.92 Billion | ▲ +25.1% |
| 2022 | 0.68x | ₩13.69 Billion | ₩9.33 Billion | ▲ +109.7% |
| 2021 | 0.33x | ₩11.16 Billion | ₩3.63 Billion | ▼ -59.1% |
| 2020 | 0.80x | ₩11.06 Billion | ₩8.80 Billion | ▲ +0.6% |
| 2019 | 0.79x | ₩12.31 Billion | ₩9.73 Billion | ▼ -12.8% |
| 2018 | 0.91x | ₩9.19 Billion | ₩8.33 Billion | ▼ -16.2% |
| 2017 | 1.08x | ₩8.67 Billion | ₩9.38 Billion | ▲ +409.1% |
| 2016 | 0.21x | ₩12.09 Billion | ₩2.57 Billion | ▼ -65.0% |
| 2015 | 0.61x | ₩9.56 Billion | ₩5.80 Billion | ▲ +152.7% |
| 2014 | 0.24x | ₩9.33 Billion | ₩2.24 Billion | — |